Progressive multifocal leukoencephalopathy

 PML is a rare disease of the central nervous system which results in the destruction of the sheath that covers the nerves. There have been reports that this has been seen in a patient treated with efalizumab.

European authorities, has issued a ‘Dear Healthcare Professional’ letter highlighting the association of progressive multifocal leukoencephalopathy (PML) with efalizumab.

Patients must be regularly monitored for any new or progressive neurological symptoms that may be suggestive of PML (impaired cognition, visual disturbances, hemiparesis, altered mental state, or behavioural changes. If PML is suspected, further dosing should be withheld until PML has been excluded.